
Natera, Inc.
NTRA
Updated: 23/09/2026, 06:58:39
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
No summaries found.
- Share price
- $390.90
- Market cap
- $55.98B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Steven Leonard Chapman
- Employees
- 6,138
- IPO date
- 01/07/2015
- Beta
- 1.534
- Last dividend
- $0.00
- Day range
- $365.20 – $391.81
- 52-week range
- $157.43 – $391.81
- 1-day performance
- 5.47%
- 1-year performance
- 148.31%
- Current drawdown (1Y)
- -0.23%
- CIK
- 0001604821
- CUSIP
- 632307104
- ISIN
- US6323071042
- Created
- 07/12/2025, 05:31:06
- Last update
- 23/09/2026, 06:58:39
Track Natera, Inc. with an AI analyst
See which prediction-market events move NTRA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 12/06/2026, 22:22:10
NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRC
Zacks Investment Research • STOCK • 08/06/2026, 14:52:27
NTRA & Diakonos Partner to Use Signatera in Refractory Melanoma Trial
Zacks Investment Research • STOCK • 01/06/2026, 16:12:12
Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
Business Wire • STOCK • 29/05/2026, 08:00:00
Natera: A Growing Biotech, After Recent FDA Approval And Q1 Revenue Results
Seeking Alpha • STOCK • 27/05/2026, 09:34:00
Natera Expands Austin Operations With New Sequencing Facility
Zacks Investment Research • STOCK • 26/05/2026, 14:01:04
Natera's EXPAND Trial Enrollment Crosses 2,000 Patient Milestone
Zacks Investment Research • STOCK • 21/05/2026, 15:31:14
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer
Zacks Investment Research • STOCK • 18/05/2026, 13:50:41
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research • STOCK • 07/05/2026, 22:00:21
SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
Business Wire • STOCK • 31/03/2026, 08:00:00
NTRA Debuts Zenith Genomics Next-Gen Sequencing Test for Rare Diseases
Zacks Investment Research • STOCK • 16/03/2026, 11:42:32
Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 12/03/2026, 02:52:17